• President Donald Trump announced a landmark agreement with Pfizer to implement "most-favored-nation" pricing for Medicaid, ensuring the U.S. pays no more than the lowest prices offered to other developed nations.

• The new TrumpRx direct-to-consumer platform, launching in 2026, will allow Americans to purchase prescription drugs at steep discounts (averaging 50 percent off retail prices), bypassing traditional pharmacy markups.

• Pfizer committed to investing $70 billion in domestic research, development, and manufacturing, aligning with Trump's push to bring pharmaceutical production back to America.

• While the deal marks progress, experts caution that discounts may still leave expensive drugs unaffordable for many, and the full impact remains unclear due to Pfizer's confidential terms.

• The administration leveraged tariff threats to secure the deal and hinted at similar agreements with other drugmakers. Critics argue systemic affordability issues persist, while Democrats and Republicans remain divided on broader healthcare reforms.

In a major move aimed at lowering prescription drug costs, President Donald Trump announced a landmark agreement with pharmaceutical giant Pfizer Inc. that includes deep discounts for Medicaid, a new direct-to-consumer drug purchasing website called "TrumpRx," and a $70 billion investment in U.S. manufacturing.